Studies currently planned for Cesamet® (nabilone) include cancer pain and symptom management, pain associated with multiple sclerosis, diabetic peripheral neuropathy, as well as current standard of care evaluation in chemotherapy-induced emesis.

Cesamet is being evaluated in a broad range of applications. Intent to study Cesamet in these applications in no way infers efficacy or safety in these conditions at this time. Please contact Valeant Pharmaceuticals International at 1-877-361-2719 if you should have any questions regarding these developmental activities. Cesamet is used to treat the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.